Gilead: Jefferies still a buyer
(CercleFinance.com) - On Tuesday Jefferies analysts confirmed their "buy" rating on the share of US bio-pharma company Gilead, with a target price of 97 dollars.
This target price is about 20 above the share's current price (meaning 24% upside potential).
"We lowered our Q2 below consensus and investors should prepare for a notable down-tick - but this should not be surprising given what they said on the Q1 call. More important is forward looking (not backwards looking)," the broker says.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
This target price is about 20 above the share's current price (meaning 24% upside potential).
"We lowered our Q2 below consensus and investors should prepare for a notable down-tick - but this should not be surprising given what they said on the Q1 call. More important is forward looking (not backwards looking)," the broker says.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.